<Dendreon should initiate a combo trial of Provenge+taxotere vs taxotere (standard of care)ASAP.
This trial would be the next logical step anyway, regardless if 9902b succeeds or fails. And could be used as a backup for approval.>
good point.
i know there are potentially significant financial considerations, but that said, i don't understand why DNDN hasn't at least tried to force a potential euro partner's (aka Sanofi's) hand by starting a provenge/tax combo trial and/or expanding 9902B clinical trial centers to europe to at least start the timeline for euro approval (assuming the euros won't just accept FDA approval as basis for euro approval).
its been pointed out by others before many times, but why not just partner now for euro & get that ball to commercialization rolling, rather than wasting 2 or 3 years waiting for US results???
it makes little sense not to, imo, as a former DNDN long, fwiw.
